NASDAQ$ABEO
Abeona Therapeutics Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Abeona Therapeutics reported financial results for the third quarter of 2023 and provided corporate updates.
Abeona Therapeutics reported a net loss attributable to common shareholders of $11.8 million for the third quarter of 2023. The company's cash, cash equivalents, restricted cash and short-term investments totaled $54.1 million as of September 30, 2023, which is expected to fund operations into the fourth quarter of 2024. The company completed its first-ever U.S. BLA submission and initiated commercial readiness activities for potential U.S. launch of pz-cel.
- Completed Abeona’s first-ever U.S. Biologics License Application (BLA) submission in September 2023.
- FDA decision on priority review and acceptance of BLA for pz-cel expected by late-November 2023.
- Initiated commercial readiness activities for potential U.S. launch of pz-cel.
- Cash, cash equivalents, restricted cash and short-term investments totaled $54.1 million as of September 30, 2023.
Headline financials
Revenue & EPS history
Abeona Therapeutics · Revenue · Quarterly
$593K
Forward guidance
Abeona estimates that its cash and cash equivalents, restricted cash and short-term investments as of September 30, 2023 are sufficient resources to fund operations into the fourth quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
-0.3%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+6.4%
Avg return
30 days after
44%
27 / 62 earnings
Positive
+18.8%
Q3 2025
Best reaction
-28.9%
Q1 2011
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -5.5% | -2.8% | |
| Q4 2025 | +6.1% | -10.1% | +8.7% | |
| Q3 2025 | +18.8% | +8.2% | +28.5% | |
| Q1 2025 | -4.2% | -2.8% | -8.1% | |
| Q4 2024 | -1.2% | -3.8% | -6.9% | |
| Q3 2024 | -3.9% | -3.4% | -3.4% | |
| Q2 2024 | +12.7% | +13.1% | +26.5% | |
| Q1 2024 | +9.5% | +6.0% | +8.8% | |
| Q4 2023 | -12.3% | -11.8% | -8.1% | |
| Q3 2023 | +3.9% | +2.4% | +15.4% | |
| Q2 2023 | +0.7% | +0.3% | +34.6% | |
| Q1 2023 | -7.2% | -5.3% | +32.8% | |
| Q4 2022 | +1.8% | +1.8% | +10.4% | |
| Q3 2022 | -8.0% | -8.0% | -32.3% | |
| Q2 2022 | +6.5% | +14.7% | -5.8% | |
| Q1 2022 | +12.5% | +0.0% | +6.3% | |
| Q4 2021 | +3.2% | +9.7% | -32.3% | |
| Q3 2021 | -5.4% | -19.6% | -43.5% | |
| Q2 2021 | -0.8% | +3.2% | +4.8% | |
| Q1 2021 | +6.5% | +6.5% | +9.0% | |
| Q4 2020 | -1.1% | -5.8% | -14.7% | |
| Q3 2020 | +11.7% | +24.3% | +41.7% | |
| Q2 2020 | +1.7% | -3.8% | -29.0% | |
| Q1 2020 | -7.2% | +29.1% | +16.3% | |
| Q4 2019 | +17.2% | +22.4% | +43.7% | |
| Q3 2019 | -6.4% | -6.8% | +60.2% | |
| Q2 2019 | +0.0% | +6.6% | +30.7% | |
| Q1 2019 | -8.2% | -3.0% | -29.3% | |
| Q4 2018 | -2.0% | -7.2% | +1.0% | |
| Q3 2018 | -22.0% | -24.1% | -13.6% | |
| Q2 2018 | -7.1% | -11.6% | -7.1% | |
| Q1 2018 | +10.9% | +11.4% | -13.8% | |
| Q4 2017 | -9.3% | -4.7% | +17.3% | |
| Q3 2017 | +6.6% | -2.6% | +9.3% | |
| Q2 2017 | +14.9% | +5.4% | +89.2% | |
| Q1 2017 | -1.6% | -1.6% | -20.8% | |
| Q4 2016 | +2.0% | +3.0% | +13.0% | |
| Q3 2016 | +5.7% | +18.0% | -15.6% | |
| Q2 2016 | +4.3% | +5.9% | +27.1% | |
| Q1 2016 | +4.1% | — | — | |
| Q4 2015 | -5.0% | — | — | |
| Q3 2015 | +1.8% | — | — | |
| Q2 2015 | -3.9% | — | — | |
| Q1 2015 | -7.2% | — | — | |
| Q4 2014 | -3.2% | — | — | |
| Q2 2014 | -3.2% | — | — | |
| Q3 2014 | -8.5% | — | — | |
| Q1 2014 | +13.6% | — | — | |
| Q2 2013 | -10.3% | — | — | |
| Q4 2013 | -10.3% | — | — | |
| Q3 2013 | -6.3% | — | — | |
| Q1 2013 | +2.2% | — | — | |
| Q4 2012 | -8.3% | — | — | |
| Q3 2012 | -7.4% | — | — | |
| Q2 2012 | +6.5% | — | — | |
| Q1 2011 | -28.9% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +13.9% | — | — | |
| Q2 2010 | -4.4% | — | — | |
| Q2 2011 | -4.4% | — | — | |
| Q4 2010 | -0.9% | — | — | |
| Q3 2010 | -0.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro